Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
PET Imaging Study of Recovered Anorexics
This study is ongoing, but not recruiting participants.
Sponsors and Collaborators: University of Pittsburgh
National Institute of Mental Health (NIMH)
Information provided by: University of Pittsburgh
ClinicalTrials.gov Identifier: NCT00603018
  Purpose

Several studies in the past suggest that individuals who have or had anorexia nervosa may have alterations in brain serotonin. Serotonin seems to play an important role in regulating anxiety, mood, and other symptoms found in anorexia nervosa. We will be using a technology called Positron Emission Tomography (PET), which is a method used to take pictures of the body, in this case, the brain. Study participants will undergo two baseline PET scans on the first day of the study. They will then be given a medication called fluoxetine (also know as Prozac) to take for 8 weeks. At the end of the 8th week, they will return for a third PET scan. By comparing the brain scans, before and after fluoxetine treatment, we can understand more about how treatment with fluoxetine affects the serotonin receptors in the brain. We will be comparing brain serotonin system in women who have recovered from anorexia with healthy control women who have never had an eating disorder in order to gain a better understanding of changes in the serotonin system associated with eating disorders. This study may help shed light on how to make fluoxetine a more effective treatment for anorexia nervosa.


Condition Intervention
Anorexia Nervosa
Drug: Fluoxetine

MedlinePlus related topics: Eating Disorders
Drug Information available for: Fluoxetine Dopamine Dopamine hydrochloride Serotonin Fluoxetine hydrochloride
U.S. FDA Resources
Study Type: Interventional
Study Design: Basic Science, Open Label, Parallel Assignment
Official Title: PET Imaging of Dopaminergic Transmission and Serotonin Markers in Anorexia Nervosa

Further study details as provided by University of Pittsburgh:

Primary Outcome Measures:
  • serotonin level [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 120
Study Start Date: June 2007
Estimated Study Completion Date: December 2008
Estimated Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1
Recovered anorexia
Drug: Fluoxetine
8 weeks of fluoxetine(2.5mg,5mg,10mg,20mg,30mg,40mg,40mg,40mg)each week per day.

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Recovered from Anorexia Nervosa
  • Not taking medication for emotional problems
  • Regular menstrual cycle

Exclusion Criteria:

  • Women who are pregnant or nursing
  • Psychoactive medications in the past 30 days
  • Neurological disorders.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00603018

Locations
United States, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
University of Pittsburgh
Investigators
Principal Investigator: Walter Kaye, M.D. UPMC
  More Information

Related Info  This link exits the ClinicalTrials.gov site

Responsible Party: University of Pittsburgh Medical Center ( Walter Kaye, MD )
Study ID Numbers: PRO06110005
Study First Received: October 16, 2007
Last Updated: October 16, 2008
ClinicalTrials.gov Identifier: NCT00603018  
Health Authority: United States: Institutional Review Board

Keywords provided by University of Pittsburgh:
eating disorders
anorexia nervosa
anorexia
PET
brain imaging
serotonin
fMRI
Prozac
fluoxetine

Study placed in the following topic categories:
Fluoxetine
Signs and Symptoms
Dopamine
Signs and Symptoms, Digestive
Mental Disorders
Anorexia
Anorexia Nervosa
Serotonin
Eating Disorders

Additional relevant MeSH terms:
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Serotonin Agents
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses
Physiological Effects of Drugs
Psychotropic Drugs
Antidepressive Agents, Second-Generation
Central Nervous System Agents
Serotonin Uptake Inhibitors
Antidepressive Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 14, 2009